Peptides for joint pain and arthritis

What’s been tested for joint pain, knee arthritis and tendon injuries, and what guidelines recommend first.

The short answer

No peptide is approved in the US for joint pain, arthritis or tendon injuries; in the UK, Synacthen Depot, a long-acting cosyntropin, is licensed for short-term use in place of steroids, including in rheumatoid arthritis. The strongest evidence is indirect: in people with obesity and knee arthritis, weight loss on semaglutide (STEP 9) and retatrutide (TRIUMPH-1) lowered knee pain more than placebo.

BPC-157’s only human knee data come from a clinic chart review without a control group, and oral calcitonin tablets didn’t slow knee arthritis in two 2-year trials of 2,206 people. Tendon, cartilage and recovery claims for BPC-157, TB-500, AOD9604 and others rest on animal studies or user reports.

24 uses on this site’s compound pages: 1 on a label, 10 tested in people, 7 in animals only, 6 claims only.

What guidelines recommend first

For knee and hip arthritis, the American College of Rheumatology strongly recommends exercise, weight loss for people with overweight, self-management programs, tai chi, a cane, knee braces, anti-inflammatory gel for the knee, anti-inflammatory tablets and steroid injections into the knee.

On a label 1

Approved uses, from a product label somewhere in the world.

CosyntropinApproved drug: LabelInflammatory bowel disease and arthritis flares. UK only: Synacthen Depot is licensed for short-term use where steroids would be used, such as ulcerative colitis, Crohn’s disease or rheumatoid arthritis, especially when steroid pills don’t suit.

Tested in people 10

Studied in people, whatever the result: some worked, many didn’t or are unproven.

SemaglutideApproved drug: TrialKnee arthritis pain. Positive, not an approved use: in STEP 9 (407 adults with obesity and knee osteoarthritis), knee pain scores fell 41.7 points vs 27.5 on placebo at 68 weeks, with weight down 13.7% vs 3.2%.
TirzepatideApproved drug: TrialPsoriasis and psoriatic arthritis, with ixekizumab. Positive, not an approved use: in open-label trials in adults with overweight or obesity, adding tirzepatide to ixekizumab (Taltz) cleared psoriasis completely in 40.6% vs 29.0% at 36 weeks (274 people). In psoriatic arthritis, 33.5% vs 20.4% improved by at least half (271 people).
RetatrutideHuman studies: TrialKnee osteoarthritis pain. Positive: among 574 TRIUMPH-1 adults with knee arthritis, the pain score (10-point scale) fell 3.2–3.6 points vs 1.9 on placebo. A dedicated knee trial hasn’t published results.
L-CarnitineApproved drug: TrialRheumatoid arthritis, added to standard drugs. Unproven: in a 12-week trial of 46 people with active rheumatoid arthritis, those taking 500 mg twice daily by mouth with their usual drugs ended with lower disease activity and pain scores than those on usual drugs alone, but there was no placebo and the groups differed at the start.
AmycretinHuman studies: TrialKnee osteoarthritis pain. Unproven: AMAZE 5 and 6 (about 400 adults each) are testing weight loss and knee pain with weekly injections; main results are expected in August 2028.
BPC-157Preclinical: TrialKnee pain. Unproven: in a clinic chart review, 11 of 12 people given BPC-157 alone by injection into the knee joint reported relief when phoned 6–12 months later. No control group.
Thymosin Beta-4Human studies: TrialInjury and joint repair. Unproven: the only human report is a clinic chart review in which 3 of 4 people given knee injections of it with BPC-157 reported relief. No control group; injection under the skin is untested.
CalcitoninApproved drug: TrialKnee osteoarthritis. Negative: two 2-year trials of oral calcitonin tablets in 2,206 people didn’t slow joint-space narrowing on X-ray. The tablets were never approved.
IcotrokinraApproved drug: TrialPsoriatic arthritis. Unproven so far: two phase 3 trials in about 1,300 adults are under way, and no results had been reported by October 2026.
ThymulinHuman studies: TrialRheumatoid arthritis. Two randomized placebo-controlled trials in 1987 found 5 mg a day best: 56% of patients rated improved against 17% on placebo, with minimal side effects. Never developed further.

Seen only in animals 7

Results in animals or cells only. Most treatments tested in animals never reach approval for people.

AOD9604Human studies: AnimalKnee osteoarthritis and cartilage repair. Unproven in people: in a 32-rabbit study of damaged knees, weekly joint injections improved cartilage, more so with hyaluronic acid (a joint lubricant). FDA found no human osteoarthritis study.
BPC-157Preclinical: AnimalTendon, ligament and muscle injuries. Unproven in people: rat studies report faster healing of injured tendons, ligaments and muscles. A 2025 systematic review found 36 orthopedic studies, 35 of them in animals or cells.
TB-500Preclinical: AnimalTendon and ligament injuries. Unproven in people: in a 2026 rat study, daily TB-500 for 4 weeks after Achilles tendon repair gave stronger, better-organized tendons. Adding BPC-157 added nothing.
CartalaxPreclinical: AnimalJoint and cartilage health (osteoarthritis). Unproven: in aging cartilage cells and human stem cells in a dish, it raised cartilage-building markers. A 2023 Russian review says oral use helped older people with osteoarthritis but cites no study.
MGFPreclinical: AnimalTendon and bone repair. Unproven in people: a synthetic version improved healing of injured rat Achilles tendons (2016) and of bone gaps in rabbits (2011). Neither use has been tested in a person.
LarazotideHuman studies: AnimalColitis, arthritis and fatty liver. Unproven in people: in mice and rats it lessened colitis, delayed arthritis onset, limited fatty liver and reduced gut leakiness in pancreatitis. None of these uses has been tested in human trials.
GHK-CuHuman studies: AnimalLung, gut and joint repair. Unproven in people: in mice it eased lung scarring and colitis, and in rats knee-ligament graft healing improved at 6 weeks but not at 12. None of these has been tested in humans.

Claims without data 6

Promoted by sellers, clinics or users, with no study behind the claim.

HGH Fragment 176-191Preclinical: No studyJoint, cartilage and muscle claims. Unproven: no study has tested this peptide for joints, cartilage or muscle in people or animals. The rabbit knee study often cited used AOD9604, a different peptide.
EcnoglutideApproved drug: No studyKnee osteoarthritis pain. Unproven: a 68-week phase 3 trial in 360 Chinese adults with obesity and knee osteoarthritis began recruiting in August 2026.
EloralintideHuman studies: No studySleep apnea and knee osteoarthritis pain. Unproven: 64-week phase 3 trials in obstructive sleep apnea and in knee osteoarthritis pain began in February 2026, with results expected in 2028.
TB-500Preclinical: CommunityFaster recovery, less pain and stiffness. Unproven: users report easier movement and less pain within weeks. FDA’s 2026 review found no study that has given TB-500 to a person for any condition.
ChonlutenPreclinical: No studyJoint and cartilage health. Some sellers market it for joints, apparently confusing it with cartilage peptides such as Cartalax; no study links it to joints.
CJC-1295 (no DAC)Preclinical: CommunityAnti-aging, skin and joints. Unproven: FDA found websites promising stronger bones, better skin and joints, mood, memory and libido (2024). None of these has been studied for any form of CJC-1295.

Side effects

Every compound’s answer, from its label, studies or user reports: Can peptides cause joint or muscle pain?

Injury recovery guide, BPC-157 vs TB-500.

The same uses among all muscles, bones and joints: evidence map. Every condition, A to Z: conditions A to Z.

Sources: Kolasinski et al., 2019 American College of Rheumatology/Arthritis Foundation osteoarthritis guideline (Arthritis Care Res 2020), PMID 31908149; Bliddal et al., STEP 9 (N Engl J Med 2024), PMID 39476339; Karsdal et al., oral salmon calcitonin in knee osteoarthritis (Osteoarthritis Cartilage 2015), PMID 25582279; Synacthen Depot UK summary of product characteristics (2025); each compound’s answer from its own page, where its sources are listed.

By Vial Guide editorsLast reviewed October 7, 2026

How we review